The tumour-suppressor protein p53 is often mutated in cancer. But it seems that p53 deficiency is not all bad, and inhibiting this protein might mitigate toxic side effects of chemotherapy and radiotherapy.
This is a preview of subscription content, log in via an institution to check access.
References
Christophorou, M. A., Ringhausen, I., Finch, A. J., Brown Swigart, L. & Evan, G. I. Nature 443, 214–217 (2006).
Efeyan, A., Garcia-Cao, I., Herranz, D., Vaelasco-Miguel, S. & Serrano, M. Nature 443, 159 (2006).
Christophorou, M. A. et al. Nature Genet. 37, 718–726 (2005).
Sherr, C. J. et al. Cold Spring Harb. Symp. Quant. Biol. 70, 129–137 (2005).
Bensaad, K. & Vousden, K. H. Nature Med. 11, 1278–1279 (2005).
Tolbert, D., Lu, X., Yin, C., Tantama, M. & Van Dyke, T. Mol. Cell. Biol. 22, 370–377 (2002).
Eymin, B. et al. Mol. Cell. Biol. 26, 4339–4350 (2006).
Bertheau, P. et al. Lancet 360, 852–854 (2002).
Westphal, C. H. et al. Cancer Res. 58, 5637–5639 (1998).
Schmitt, C. A. et al. Cancer Cell 1, 289–298 (2002).
Strom, E. et al. Nature Chem. Biol. 2, 474–479 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Berns, A. Can less be more for p53?. Nature 443, 153–154 (2006). https://doi.org/10.1038/443153a
Published:
Issue Date:
DOI: https://doi.org/10.1038/443153a
- Springer Nature Limited
This article is cited by
-
Changes in allelic imbalances in locally advanced breast cancers after chemotherapy
British Journal of Cancer (2007)